Adverse events
Erenumab and galcanezumab appear to have a favourable safety profile. Approximately, 37% of the patients treated with each CGRP MoAb suffered a drug-related adverse event (Table 1 ). In fact, only 1 (1,20%) patient treated with erenumab and 1 receiving galcanezumab (1,79%) had to stop the treatment due to paresthesia and toxicodermia, respectively.